KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced ...
Generative AI is all the rage and pushes past the trivial deep neural networks (DNNs) of yore. On the neural-network side, we have DNNs, artificial neural networks (ANNs), convolutional neural ...
Recursion is using artificial intelligence and machine learning to accelerate drug research and development. The company benefits from partnerships with major tech and healthcare leaders, reaffirming ...
Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...
Screening libraries will leverage Recursion's MatchMaker tool to identify compounds across Enamine REAL Space predicted to bind to high-value targets. KYIV, Ukraine and SALT LAKE CITY, Dec. 20, 2023 ...
Recursion believes that these new libraries will be of interest to customers given the additional predictive insights via MatchMaker. The tool employs machine learning to evaluate the suitability of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback